ValuEngine upgraded shares of Allogene Therapeutics (NASDAQ:ALLO) from a hold rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.

A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded Allogene Therapeutics from a buy rating to a hold rating in a report on Monday, August 12th. BTIG Research started coverage on Allogene Therapeutics in a report on Friday, August 9th. They issued a buy rating and a $37.00 price target for the company. JPMorgan Chase & Co. reissued a hold rating and issued a $29.00 price target on shares of Allogene Therapeutics in a report on Wednesday. William Blair reissued a buy rating on shares of Allogene Therapeutics in a report on Tuesday, November 5th. Finally, Canaccord Genuity started coverage on Allogene Therapeutics in a research note on Monday, November 4th. They set a buy rating and a $36.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $36.11.

Allogene Therapeutics stock traded up $0.88 during trading on Thursday, hitting $27.32. The company’s stock had a trading volume of 577,200 shares, compared to its average volume of 416,218. The stock has a market capitalization of $3.37 billion and a price-to-earnings ratio of -4.15. Allogene Therapeutics has a 1-year low of $23.37 and a 1-year high of $33.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.46 and a current ratio of 13.46. The stock’s fifty day moving average is $27.85 and its 200 day moving average is $28.07.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. On average, research analysts anticipate that Allogene Therapeutics will post -1.95 EPS for the current fiscal year.

In other Allogene Therapeutics news, insider Alison Moore sold 48,827 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $32.11, for a total transaction of $1,567,834.97. Corporate insiders own 36.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALLO. Vanguard Group Inc. raised its stake in Allogene Therapeutics by 64.0% during the second quarter. Vanguard Group Inc. now owns 3,443,180 shares of the company’s stock valued at $92,449,000 after buying an additional 1,343,459 shares in the last quarter. BlackRock Inc. raised its position in shares of Allogene Therapeutics by 58.3% during the 2nd quarter. BlackRock Inc. now owns 3,562,333 shares of the company’s stock worth $95,650,000 after purchasing an additional 1,312,056 shares during the period. LLBH Private Wealth Management LLC raised its position in shares of Allogene Therapeutics by 652.8% during the 2nd quarter. LLBH Private Wealth Management LLC now owns 1,155,717 shares of the company’s stock worth $31,031,000 after purchasing an additional 1,002,199 shares during the period. Nuveen Asset Management LLC acquired a new stake in shares of Allogene Therapeutics during the 2nd quarter worth approximately $14,967,000. Finally, Wildcat Capital Management LLC acquired a new stake in shares of Allogene Therapeutics during the 2nd quarter worth approximately $14,289,000. Hedge funds and other institutional investors own 54.48% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Story: Equal Weight Rating

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.